AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22966077 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose feeding (1 g/(kg·d) for 3 d)
Number of subjects: 12
Study 22966077 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose feeding (1 g/(kg·d) for 3 d)
Number of subjects: 12
Study 22966077 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin feeding (1 g/(kg·d) for 3 d)
Number of subjects: 12
Study 22966077 — intervention group
Group type: COMPARATOR
Intervention: No supplementary WSC (control)
Number of subjects: 12
Study 20591890 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG (CPB)
Number of subjects: 71
Study 20591890 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG (OPCAB)
Number of subjects: 71
Study 20591890 — intervention group
Group type: COMPARATOR
Intervention: Control group (CPB)
Number of subjects: 71
Study 20591890 — intervention group
Group type: COMPARATOR
Intervention: Control group (OPCAB)
Number of subjects: 71
Study 16480971 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological overlap with strong orthographic overlap (e.g., dream-gleam)
Number of subjects: 0
Study 16480971 — intervention group
Group type: COMPARATOR
Intervention: Phonological overlap with weak orthographic overlap
Number of subjects: 0
Study 16480971 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological priming in pseudoword detection task
Number of subjects: 0
Study 15700891 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 0.02-0.2 microg/kg
Number of subjects: 14
Study 15700891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 12388963 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol (400 microg every 4 hours)
Number of subjects: 114
Study 12388963 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (200 microg every hour for 3 hours followed by 400 microg every 4 hours)
Number of subjects: 114
Study 9915282 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of dialysis (target eKt/V 1.05)
Number of subjects: 426
Study 9915282 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of dialysis (target eKt/V 1.45)
Number of subjects: 426
Study 7780250 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotonic oral rehydration solution (ORS)
Number of subjects: 60
Study 7780250 — intervention group
Group type: COMPARATOR
Intervention: Standard WHO‐ORS
Number of subjects: 60
Study 1399929 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ciprofloxacin
Number of subjects: 133
Study 1399929 — intervention group
Group type: COMPARATOR
Intervention: Azlocillin and netilmicin
Number of subjects: 133
Study 3160356 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg once daily)
Number of subjects: 40
Study 3160356 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg once daily)
Number of subjects: 40
Study 3160356 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of atenolol and nitrendipine (100 mg and 20 mg respectively, once daily)
Number of subjects: 40
Study 3160356 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (Atenolol + Nitrendipine)
Number of subjects: 40
Study 30934881 — intervention group
Group type: EXPERIMENTAL
Intervention: 20,000 IU of vitamin D3/week for 12 weeks
Number of subjects: 200
Study 30934881 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 200
Study 29389505 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported questionnaires measuring general well-being, sense of coherence, self-efficacy of diabetes management, experiences of diabetes management during breastfeeding
Number of subjects: 155
Study 29389505 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported questionnaires measuring general well-being
Number of subjects: 155
Study 29389505 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported questionnaires measuring sense of coherence
Number of subjects: 155
Study 27094189 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg per day (with option to increase to 40 mg)
Number of subjects: 62
Study 27094189 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one capsule)
Number of subjects: 62
Study 25082363 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance measures during prostate radiotherapy
Number of subjects: 0
Study 25082363 — intervention group
Group type: EXPERIMENTAL
Intervention: Major protocol variations
Number of subjects: 0
Study 25082363 — intervention group
Group type: EXPERIMENTAL
Intervention: Level III phantom-based dosimetry study
Number of subjects: 0
Study 25082363 — intervention group
Group type: EXPERIMENTAL
Intervention: Set-up accuracy study
Number of subjects: 0
Study 25082363 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-accruing centres
Number of subjects: 0
Study 25082363 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance variables
Number of subjects: 0
Study 24500507 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight retention in postpartum period among women who were overweight (9.9 ± 7.7 kg)
Number of subjects: 715
Study 24500507 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight retention more than 10 kg in postpartum
Number of subjects: 715
Study 24500507 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of overweight prevalence
Number of subjects: 715
Study 24500507 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of factors with weight retention
Number of subjects: 715
Study 21607780 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ketoprofen 2 mg/kgBW
Number of subjects: 120
Study 21607780 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. paracetamol 15 mg/kgBW
Number of subjects: 120
Study 21607780 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of i.v. ketoprofen and i.v. paracetamol
Number of subjects: 120
Study 21607780 — intervention group
Group type: COMPARATOR
Intervention: Control (paracetamol)
Number of subjects: 120
Study 18281734 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of omeprazole
Number of subjects: 14
Study 18281734 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of omeprazole
Number of subjects: 14
Study 18281734 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of ritonavir with 800 mg of indinavir and 40 mg of omeprazole
Number of subjects: 14
Study 18281734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 17171191 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release zolpidem
Number of subjects: 0
Study 14586908 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory training of strength, functional performance, and balance 3 times a week for 3 months
Number of subjects: 57
Study 14586908 — intervention group
Group type: COMPARATOR
Intervention: Placebo activities
Number of subjects: 57
Study 10722989 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician advice on physical activity
Number of subjects: 54
Study 9643668 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (TER) 1 mg, 2 mg, and 5 mg once daily in the evening for 15 days
Number of subjects: 50
Study 9643668 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (TAM) 0.4 mg once daily after breakfast for 15 days
Number of subjects: 50
Study 8196850 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetin (20 mg/die) and cyclobenzaprine (10 mg/die)
Number of subjects: 21
Study 8196850 — intervention group
Group type: COMPARATOR
Intervention: Cyclobenzaprine (10 mg/die)
Number of subjects: 21
Study 3286577 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir (400 mg three times a day on Days -6 to +14 and 200 mg three times a day on Days +15 to +90 for adults; 500 mg/m2 per day divided into three doses on Days -6 to +14 and 250 mg/m2 per day divided into three doses on Days +15 to +90 for children)
Number of subjects: 34
Study 3286577 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 untreated HSV-seropositive BMT recipients)
Number of subjects: 34
Study 3286577 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 34
Study 3286577 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 34
Study 29467019 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR care pathway intervention (assessment clinic appointment and up to six telephone follow-up calls over 12 months)
Number of subjects: 381
Study 29467019 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR care pathway intervention
Number of subjects: 381
Study 29467019 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 381
Study 27317249 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video instruction
Number of subjects: 502
Study 27317249 — intervention group
Group type: COMPARATOR
Intervention: Non-video (control) group
Number of subjects: 502
Study 25314058 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher β-carotene levels
Number of subjects: 29046
Study 25314058 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher retinol levels
Number of subjects: 29046
Study 25314058 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher α-tocopherol levels
Number of subjects: 29046
Study 22649258 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended soup meal
Number of subjects: 40
Study 22649258 — intervention group
Group type: COMPARATOR
Intervention: Solid/liquid meal
Number of subjects: 40
Study 20595658 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg daily)
Number of subjects: 15603
Study 20595658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15603
Study 18821888 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic wedge positioning (group W)
Number of subjects: 78
Study 18821888 — intervention group
Group type: COMPARATOR
Intervention: 20 degrees Trendelenberg tilt (group T)
Number of subjects: 78
Study 15668621 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid HIV testing and counseling in 1 visit
Number of subjects: 3297
Study 15668621 — intervention group
Group type: COMPARATOR
Intervention: Standard HIV testing and counseling in 2 visits
Number of subjects: 3297
Study 15668621 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid HIV testing and counseling in 1 visit (among men)
Number of subjects: 3297
Study 15668621 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid HIV testing and counseling in 1 visit (among men who had sex with men)
Number of subjects: 3297
Study 15668621 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid HIV testing and counseling in 1 visit (among persons with no STDs at enrollment)
Number of subjects: 3297
Study 12059988 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg day(‐1))
Number of subjects: 52
Study 12059988 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (4 g day(‐1))
Number of subjects: 52
Study 7660770 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonography group (39 women)
Number of subjects: 80
Study 7660770 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy group (41 women)
Number of subjects: 80
Study 7660770 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall success rate
Number of subjects: 80
Study 7660770 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterosalpingography (HSG) results
Number of subjects: 80
Study 2607126 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 2607126 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0
Study 31254485 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocuff-assisted colonoscopy (EAC)
Number of subjects: 513
Study 31254485 — intervention group
Group type: COMPARATOR
Intervention: Transparent hood-assisted colonoscopy (TAC)
Number of subjects: 513
Study 27693108 — intervention group
Group type: COMPARATOR
Intervention: RBT
Number of subjects: 135
Study 27693108 — intervention group
Group type: COMPARATOR
Intervention: RBTRH
Number of subjects: 135
Study 27693108 — intervention group
Group type: EXPERIMENTAL
Intervention: RBTSPRH
Number of subjects: 135
Study 25946938 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at true points (ST36, SP6, LI4)
Number of subjects: 100
Study 25946938 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (touching at the same points)
Number of subjects: 100
Study 23645311 — intervention group
Group type: EXPERIMENTAL
Intervention: Real modulation (R)
Number of subjects: 32
Study 23645311 — intervention group
Group type: COMPARATOR
Intervention: Sham modulation (S)
Number of subjects: 32
Study 21325151 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (cumulative dose, 0.4 μg/kg)
Number of subjects: 73
Study 21325151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 20031900 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg
Number of subjects: 17802
Study 17804382 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 1 (lower trauma exposure)
Number of subjects: 149
Study 17804382 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 2 (higher trauma exposure)
Number of subjects: 149
Study 15562081 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline approach
Number of subjects: 50
Study 15562081 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedian approach
Number of subjects: 50
Study 11567703 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed patients (local and systemic warming)
Number of subjects: 421
Study 11567703 — intervention group
Group type: COMPARATOR
Intervention: Non-warmed patients (standard group)
Number of subjects: 421
Study 11567703 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed patients
Number of subjects: 421
Study 11567703 — intervention group
Group type: COMPARATOR
Intervention: Non-warmed patients
Number of subjects: 421
Study 9593014 — intervention group
Group type: EXPERIMENTAL
Intervention: HDCV three-injection regimen
Number of subjects: 312
Study 9593014 — intervention group
Group type: EXPERIMENTAL
Intervention: PVRV three-injection regimen
Number of subjects: 312
Study 9593014 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster injection at 1 year
Number of subjects: 312
Study 9593014 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody titers 2 weeks after the 1‐year booster
Number of subjects: 312
Study 9593014 — intervention group
Group type: EXPERIMENTAL
Intervention: Good responders (titers > or = 30 IU/mL)
Number of subjects: 312
Study 7947412 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic schizophrenic patients
Number of subjects: 72
Study 7947412 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 72
Study 7947412 — intervention group
Group type: COMPARATOR
Intervention: Alcoholic controls
Number of subjects: 72
Study 2698461 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (2 x 12.5 mg) in addition to standard treatment (digitalis and diuretics)
Number of subjects: 8
Study 2698461 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (digitalis and diuretics)
Number of subjects: 8
Study 1071872 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent reading of ECG-Case summary sheets (2 or 4 occasions)
Number of subjects: 8
Study 1071872 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference to coronary arteriographic information
Number of subjects: 8
Study 31941696 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned early delivery
Number of subjects: 0
Study 31941696 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 0
Study 31348088 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forests (RF) classifier with 10,000 trees, each tree using 15 randomly selected cases and 20 randomly selected features (SUV ratio per region of interest)
Number of subjects: 57
Study 28845908 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 35
Study 25409838 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic myotomy (LM)
Number of subjects: 53
Study 25409838 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic dilatation (PD)
Number of subjects: 53
Study 23401434 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose helical computed tomography (LDCT)
Number of subjects: 53454
Study 23401434 — intervention group
Group type: COMPARATOR
Intervention: Chest radiography (CXR)
Number of subjects: 53454
Study 22152404 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 99
Study 22152404 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 99
Study 22152404 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 99
Study 19149880 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Physical Therapy (APT)
Number of subjects: 70
Study 19149880 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Physical Therapy (PPT)
Number of subjects: 70
Study 19149880 — intervention group
Group type: COMPARATOR
Intervention: Activity as Usual (AAU)
Number of subjects: 70
Study 17189096 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500mg once a day for 3 days)
Number of subjects: 342
Study 17189096 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (400mg once a day for 5 days)
Number of subjects: 342
Study 15124700 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy (MT) consisting of mercaptopurine and cytarabine for 18 months
Number of subjects: 309
Study 15124700 — intervention group
Group type: COMPARATOR
Intervention: No maintenance therapy (control group)
Number of subjects: 309
Study 12548362 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo‐TD (transdermal apomorphine)
Number of subjects: 21
Study 12548362 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐dopa plus Apo‐TD
Number of subjects: 21
Study 12548362 — intervention group
Group type: COMPARATOR
Intervention: L‐dopa alone or L‐dopa plus oral dopamine‐agonists
Number of subjects: 21
Study 9638687 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal cigarette exposure
Number of subjects: 131
Study 9638687 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal marihuana exposure
Number of subjects: 131
Study 8030657 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (1 mg/kg/day; group 1)
Number of subjects: 43
Study 8030657 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous gammaglobulin (400 mg/kg on days 1 through 5; group 2)
Number of subjects: 43
Study 8030657 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both agents (group 3)
Number of subjects: 43
Study 8030657 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone (group 1)
Number of subjects: 43
Study 8030657 — intervention group
Group type: COMPARATOR
Intervention: High-dose intravenous gammaglobulin (group 2)
Number of subjects: 43
Study 2606207 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory and tactile cues
Number of subjects: 37
Study 2606207 — intervention group
Group type: COMPARATOR
Intervention: Auditory cues
Number of subjects: 37
Study 1106739 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine 1%
Number of subjects: 0
Study 1106739 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5%
Number of subjects: 0
Study 1106739 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.75%
Number of subjects: 0
Study 1106739 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine with adrenaline 1:200,000
Number of subjects: 0
Study 1106739 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 0
Study 31079356 — intervention group
Group type: EXPERIMENTAL
Intervention: Yimitasvir 30 mg
Number of subjects: 56
Study 31079356 — intervention group
Group type: EXPERIMENTAL
Intervention: Yimitasvir 100 mg
Number of subjects: 56
Study 31079356 — intervention group
Group type: EXPERIMENTAL
Intervention: Yimitasvir 200 mg
Number of subjects: 56
Study 31079356 — intervention group
Group type: EXPERIMENTAL
Intervention: Yimitasvir 400 mg
Number of subjects: 56
Study 31079356 — intervention group
Group type: EXPERIMENTAL
Intervention: Yimitasvir 100 mg once daily for 7 days
Number of subjects: 56
Study 31079356 — intervention group
Group type: EXPERIMENTAL
Intervention: Yimitasvir 200 mg once daily for 7 days
Number of subjects: 56
Study 31079356 — intervention group
Group type: COMPARATOR
Intervention: Standardized high-fat meal
Number of subjects: 56
Study 28384237 — intervention group
Group type: EXPERIMENTAL
Intervention: Need-supportive physical activity intervention
Number of subjects: 48
Study 28384237 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 48
Study 25223731 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg selisistat
Number of subjects: 55
Study 25223731 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg selisistat
Number of subjects: 55
Study 25223731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 24235227 — intervention group
Group type: EXPERIMENTAL
Intervention: Vectormune FP MG vaccination
Number of subjects: 0
Study 24235227 — intervention group
Group type: EXPERIMENTAL
Intervention: FMG revaccination at 45 weeks of age
Number of subjects: 0
Study 24235227 — intervention group
Group type: COMPARATOR
Intervention: FMG vaccination in M. gallisepticum-clean hens
Number of subjects: 0
Study 24235227 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0
Study 21621660 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 60
Study 21621660 — intervention group
Group type: COMPARATOR
Intervention: Active Exercise
Number of subjects: 60
Study 21621660 — intervention group
Group type: COMPARATOR
Intervention: Passive Treatment
Number of subjects: 60
Study 21621660 — intervention group
Group type: COMPARATOR
Intervention: Control (Education Booklet)
Number of subjects: 60
Study 19817313 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 0
Study 17033604 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 3x300 mg before reperfusion, and 8 and 16 h after reperfusion
Number of subjects: 23
Study 17033604 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% 3x100 mL
Number of subjects: 23
Study 17033604 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 23
Study 12589529 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine surfactant (100 mg/kg intratracheally under continuous ventilation and PEEP)
Number of subjects: 35
Study 12589529 — intervention group
Group type: COMPARATOR
Intervention: Nonsurfactant treatment
Number of subjects: 35